Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia

Autor: Tengiz Tsertsvadze, Amiran Gamkrelidze, Muazzam Nasrullah, Lali Sharvadze, Juliette Morgan, Shaun Shadaker, Lia Gvinjilia, Maia Butsashvili, David Metreveli, Vakhtang Kerashvili, Marina Ezugbaia, Nikoloz Chkhartishvili, Akaki Abutidze, Valeri Kvaratskhelia, Francisco Averhoff
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-7 (2020)
Druh dokumentu: article
ISSN: 1471-2334
DOI: 10.1186/s12879-019-4741-5
Popis: Abstract Background Georgia has one of the highest HCV prevalence in the world and launched the world’s first national HCV elimination programs in 2015. Georgia set the ambitious target of diagnosing 90% of people living with HCV, treating 95% of those diagnosed and curing 95% of treated patients by 2020. We report outcomes of Sofosbuvir (SOF) based treatment regimens in patients with chronic HCV infection in Georgia. Methods Patients with cirrhosis, advanced liver fibrosis and severe extrahepatic manifestations were enrolled in the treatment program. Initial treatment consisted of SOF plus ribavirin (RBV) with or without pegylated interferon (INF). Sustained virologic response (SVR) was defined as undetectable HCV RNA at least 12 weeks after the end of treatment. SVR were calculated using both per-protocol and modified intent-to-treat (mITT) analysis. Results for patients who completed treatment through 31 October 2018 were analyzed. Results Of the 7342 patients who initiated treatment with SOF-based regimens, 5079 patients were tested for SVR. Total SVR rate was 82.1% in per-protocol analysis and 74.5% in mITT analysis. The lowest response rate was observed among genotype 1 patients (69.5%), intermediate response rate was achieved in genotype 2 patients (81.4%), while the highest response rate was among genotype 3 patients (91.8%). Overall, SOF/RBV regimens achieved lower response rates than IFN/SOF/RBV regimen (72.1% vs 91.3%, P
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje